<DOC>
	<DOCNO>NCT00299962</DOCNO>
	<brief_summary>This Phase I study evaluate safety two dos BG00001 different dos interval . Eligible subject : - malignant pleural mesothelioma , - pleural effusion progress least one prior therapy refuse therapy BG00001 give twice catheter pleural space .</brief_summary>
	<brief_title>Gene Therapy Pleural Malignancies</brief_title>
	<detailed_description>Ad.hIFN-β ( BG00001 ) replication-defective recombinant adenoviral vector contain human interferon-beta ( hIFN-β ) gene . This Phase I study design evaluate safety maximum tolerate dose ( MTD ) two dos intrapleural ( IP ) Ad.hIFN-β subject pleural malignancy either metastatic pleural mesothelioma . Five dose level study : - Dose level 1 , 2 , 3 give Days 1 15 - Dose level 4 5 give Days 1 8</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>must malignant pleural effusion mesothelioma metastatic primary lung , breast , gastrointestinal , genitourinary , melanoma , sarcoma must evaluable disease must ECOG performance status 2 must pleural space involve tumor accessible pleural catheter must FEV1 &gt; 1 liter 40 % predict value must complete radiotherapy and/or treatment chemotherapy , cytotoxic , immunologic agent 4 week prior dose BG00001 concurrent Tarceva allow patient stable dose least three month serious adverse event patient stable dose hormone may continue use hormone patient stable dose Tarceva 3 month without complication may remain Tarceva malignant pleural effusion secondary lymphoma rapidly reaccumulating , symptomatic malignant pleural effusion require immediate mechanical chemical pleurodesis palliation untreated brain metastasis use concurrent systemic steroid immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gene therapy</keyword>
	<keyword>immunotherapy</keyword>
</DOC>